Meeting
2019 ASCO Annual Meeting
POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.
Authors
David Lau
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
David Lau , David Cunningham , Angela Gillbanks , Richard Crux , Rachel Powell , Eleftheria Kalaitzaki , Nicola E. Annels , Francesco Sclafani , Marco Gerlinger , Ian Chau , Ian Tomlinson , Naureen Starling , Hardev S. Pandha , David N. Church , Tony Dhillon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03827044
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS3615)
DOI
10.1200/JCO.2019.37.15_suppl.TPS3615
Abstract #
TPS3615
Poster Bd #
107a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer—A randomized phase III trial.
First Author: Thomas Aparicio
Poster
2018 Gastrointestinal Cancers Symposium
Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.
First Author: Shusuke Yagi
Poster
2023 ASCO Quality Care Symposium
Impact of the IDEA collaboration study on practice patterns of adjuvant chemotherapy in patients with stage III colon cancer: A population-based study.
First Author: Sunil Samnani
Poster
2023 ASCO Annual Meeting
A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.
First Author: Rona Yaeger